<DOC>
	<DOCNO>NCT01670279</DOCNO>
	<brief_summary>The purpose study assess safety tolerability ascend multiple oral dos brexpiprazole adjunctive therapy treatment elderly subject MDD .</brief_summary>
	<brief_title>Phase 1 Study Assess Safety/Tolerability Brexpiprazole Adjunctive Therapy Elderly Subjects With Major Depressive Disorder</brief_title>
	<detailed_description>This phase 1 , multicenter , randomize , double-blind , placebo-controlled , multiple ascend dose trial 3 sequential cohort elderly subject ( age 70 85 year old ) MDD . Brexpiprazole administer adjunct treatment current antidepressant therapy subject receive . Total individual subject duration expect 119 day ( 30-day screening period , 14-day washout period , 45-day in-clinic treatment period , 30-day follow-up last dose trial medication ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>Subjects able provide write informed consent Ability understand nature trial follow protocol requirement Male female patient 70 85 year age Subjects normal clinically stable finding physical examination , medical history , clinical laboratory determination , ECGs relation age BMI 18 35 kg/m2 . Stable subject principal psychiatric diagnosis MDD Subjects willing discontinue prohibit psychotropic prohibit medication Sexually active male practice 2 different method birth control trial 30 day last dose trial medication remain abstinent trial 30 day last dose Subjects vagus nerve stimulation device implant received ECT within 6 month Screening Subjects current Axis I ( DSMIVTR ) diagnosis : Delirium , dementia , amnestic , cognitive disorder Eating disorder ( include anorexia nervosa bulimia ) Obsessivecompulsive disorder Panic disorder Posttraumatic stress disorder current prior Axis I ( DSMIVTR ) diagnosis Schizophrenia , schizoaffective disorder , psychotic disorder , Bipolar I II disorder bipolar disorder otherwise specify Subjects clinically significant current Axis II ( DSMIVTR ) diagnosis borderline , antisocial , paranoid , schizoid , schizotypal , histrionic personality disorder Subjects experience hallucination , delusion , psychotic symptomatology Subjects Active Suicidal Ideation Some Intent Act whose recent episode occur within last 6 month Subjects meet DSMIVTR criterion substance abuse dependence within past 180 day Subjects hypothyroidism hyperthyroidism and/or abnormal result free T4 Screening Subjects currently clinically significant neurological , hepatic , renal , metabolic , hematological , immunological , cardiovascular , pulmonary , gastrointestinal disorder Subjects IDDM Subjects uncontrolled hypertension ( DBP &gt; 95 mmHg ) symptomatic hypotension Subjects epilepsy , history epilepsy , history seizure Subjects positive drug screen cocaine drug abuse The following laboratory test ECG result exclusionary : 1 . Platelets ≤ 75,000/mm3 2 . Hemoglobin ≤ 9 g/dL 3 . Neutrophils , absolute ≤ 1000/mm3 4 . AST &gt; 3 × upper limit normal 5 . ALT &gt; 3 × upper limit normal 6 . Creatinine ≥ 2 mg/dL 7 . HbA1c ≥ 7 % 8 . QTcF ≥ 450 msec Treatment MAOI within 2 week prior first dose trial medication Use benzodiazepines and/or hypnotic within 1 week prior first dose trial medication Use oral neuroleptic within 30 day prior longacting approve neuroleptic ≤ 1 full cycle plus 14 day prior first dose trial medication Day 1 Prohibited concomitant medication use prior randomization anticipate need medication trial Subjects would likely require prohibited concomitant therapy trial Subjects receive brexpiprazole prior clinical trial Subjects history neuroleptic malignant syndrome Subjects history true allergic response 1 class medication Prisoners subject compulsorily detain treatment either psychiatric physical illness Subjects participate clinical trial within last 180 day participate 2 clinical trial within past year .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Major Depressive Disorder ( MDD )</keyword>
</DOC>